During times of economic woes and plans for cost-cutting measures for many companies, the top 20 R&D players continue to spend record amounts on research and development. For 2009, three-fourths of these companies spent more on R&D than they did during the previous year, and a similar output continued into 2010.
Roche remained the industry’s leading spender on research and development in 2009, topping $9 billion during that year. Roche’s pipeline includes 60 new molecular entities and 40 additional indications for already-marketed products.
The following information is included for the top 20 pipelines, which were determined based on their healthcare R&D expenditure generated during 2009:
- Each pipeline products’ chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer
- Pipeline status details preclinical development, Phase I, Phase II, Phase III, and awaiting approval
- Region of development includes the U.S., Europe, and Japan